comparemela.com
Home
Live Updates
New Dawn for Aldosterone as Drug Target in Hypertension? : comparemela.com
'New Dawn' for Aldosterone as Drug Target in Hypertension?
Treatment with the aldosterone synthase inhibitor lorundrostat significantly decreased automated office systolic blood pressure in adults with uncontrolled hypertension in the phase 2 TARGET-HTN trial.
Related Keywords
Cleveland ,
Ohio ,
United States ,
United Kingdom ,
American ,
Steven Nissen ,
Cincor Pharma Astrazeneca ,
Luke Laffin ,
Bryan Williams ,
Journal Of The American Medical Association ,
Gordy Health ,
University College London ,
Heart Vascular Thoracic Institute At Cleveland Clinic ,
Astrazeneca ,
American Heart Association ,
Lucidact Health ,
Medtronic ,
Mineralys Therapeutics ,
Heart Vascular ,
Thoracic Institute ,
Cleveland Clinic ,
American Medical Association ,
Therapies Targeting ,
Crispr Therapeutics ,
Hypertension ,
Myocardial Infarction ,
Blood ,
Heart Failure ,
Uncontrolled Hypertension ,
Obesity ,
Bese ,
Antihypertensive ,
Heart ,
Chronic Renal Failure ,
Hronic Kidney Failure ,
Hronic Kidney Disease Ckd ,
Chronic Kidney Disease ,
Kd ,
Plasma ,
Renal Failure ,
Enal Insufficiency ,
Idney Insufficiency ,
Kidney Failure ,
Sleep Apnea ,
Sleep Disorder ,
Metabolic Syndrome ,
Obstructive Sleep Apnea ,
Renal Disease ,
Idney Di ,
comparemela.com © 2020. All Rights Reserved.